Vesicular stomatitis is a zoonotic viral disease that primarily affects equines, cattle and swine. The virus can also infect sheep and goats as well as wildlife.
In 2018, the global Vesicular Stomatitis (VS) Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Vesicular Stomatitis (VS) Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Vesicular Stomatitis (VS) Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Boehringer Ingelheim
Merck & Co
Zoetis
Vedco
Elanco
Ceva Santé Animale
Vibrac
Vetoquinol
IDEXX Laboratories
Covetrus
Neogen

Market segment by Type, the product can be split into

Symptomatic Medications
Vaccination

Market segment by Application, split into

Veterinary Hospitals
Veterinary Clinics
Retail Pharmacies

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Vesicular Stomatitis (VS) Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Vesicular Stomatitis (VS) Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Vesicular Stomatitis (VS) Therapeutics are as follows:
History Year: 2014-2018

Base Year:

2018

Estimated Year:

2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.